Recommended NZ | Guide to Money | Gimme: Competitions - Giveaways

NZ Patient First In World To Trial New Stent System

Fuseworks Media
Fuseworks Media

Wellington, Dec 2 NZPA - A New Zealand patient has become the first in the world to test a new drug-eluting coronary stent system being developed by an American company, Micell Technologies Inc.

A co-principal investigator in the clinical trial, John Ormiston -- a doctor at Auckland's Mercy Hospital -- said today that the technology represented a "significant advance in interventional cardiology," but human tests were required to address "the rare but potentially catastrophic consequences of late in-stent thrombosis".

A stent is a narrow tube inserted into a narrowed artery to keep it open, often after plaque clogging the artery has been crushed and flattened using a balloon angioplasty.

The first-in-human trial is testing the Dessolve I developed by Micell, a North Carolina biomedical device maker.

Another 29 patients in New Zealand, Belgium, and Australia -- each with documented stable or unstable angina pectoris or ischemia -- are due to trial the specialised stent system, which treats patients with lesions in the coronary arteries.

The system uses fluid technology that delivers drugs into the surrounding tissue of the affected artery in a controlled manner. In pre-clinical trials, the drug completely elutes and the polymer is eliminated within 90 days in vivo, leaving in a bare metal stent embedded in the artery, the company said in a statement.

Micell chief executive Arthur Benvenuto said the technology combined the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

All articles and comments on have been submitted by our community of users. Please notify us if you believe an item on this site breaches our community guidelines.